Heart in Diabetes 2020 Evaluation Questions

We greatly value and appreciate your opinion on the quality of the overall program.

Question Title

* 1. My specialty is:

Cardiology

Endocrinology

Primary Care

Other

Question Title

* 2. The content that most resonated with me during the presentation was the

Progression of heart failure and its implications

FARXIGA® (dapagliflozin) mechanism of action

DECLARE efficacy data

DAPA-HF efficacy data

Overall safety data

Question Title

* 3. The mechanism of action was clearly presented and aided in my understanding of FARXIGA’s new indication.

Strongly Agree

Agree

Neutral

Disagree

Strongly Disagree

Question Title

* 4. The content presented made me think differently about how I manage heart failure risks in my patients, regardless of type 2 diabetes status.

Strongly Agree

Agree

Neutral

Disagree

Strongly Disagree

Question Title

* 5. Based on information I heard during this presentation, I feel adequately prepared to prescribe FARXIGA in my practice mostly because

I understand which patients are candidates for treatment

I understand FARXIGA’s mechanism of action

I understand FARXIGA’s dosing information

I am impressed by FARXIGA’s efficacy data

I am impressed by FARXIGA’s safety data

Not applicable (I do not feel adequately prepared to prescribe FARXIGA)

Question Title

* 6. I will share the the following information presented in the product theater with my peers:

Which patients are candidates for treatment

FARXIGA’s mechanism of action

FARXIGA’s dosing information

FARXIGA’s efficacy data

FARXIGA’s safety data

Not applicable (I would not share any information on FARXIGA)

Question Title

Please see full US Prescribing Information for FARXIGA.

FARXIGA is a registered trademark of the AstraZeneca group of companies.
©2020 AstraZeneca. All rights reserved. US-41115 Last Updated 5/20